ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies
Sessions Highlight Off-The-Shelf, CRISPR Approaches
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
You may also be interested in...
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.